Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
FRIEDLANDS 10.000-JAHRE-SCHOCK: Der Kupfer-Engpass hat begonnen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
337 Leser
Artikel bewerten:
(1)

Metwood, Inc.: Emerge Nutraceuticals a Wholly Owned Subsidiary of Metwood Inc., Signs MOU to Acquire Cholesterade

MOUNT DORA, FL / ACCESSWIRE / July 18, 2022 / Today, Metwood (OTC PINK:MTWD), Emerge Nutraceuticals, has announced that they have entered into a MOU to acquire Cholesterade®, from Go Epic Health, Inc., a wholly owned subsidiary of LEON ( LEON ) for an undisclosed number of shares and is expected to close sometime within the 3 rd quarter.

Cholesterade ® is a natural, acai-fiber-based powder supplement containing 7 grams of fiber per

serving and easily soluble in water. It comes in three flavors: Mixed Berry, Orange and Lemon Lime. Clinically proven to reduce cholesterol over 8 weeks. The creator of this revolutionary product is none other than Dr. J. Robert Cade. Dr. J. Robert Cade was an American physician, university professor, research scientist and inventor. He is most widely remembered as the leader of the research team that formulated the sports drink Gatorade®. www.Cholesterade.com

Emerge Nutraceuticals (MTWD) is a nutraceutical manufacturer selling proprietary soft gels, powders, and liquid formulations for vitamins, proteins and the body-building industry. The company has their own branded products in addition to wholesale white label manufacturing. The mission is to deliver organic, healthy solutions and natural alternatives to individuals seeking non-prescription remedies to better their health. www.emergenutraceuticals.com

About Emerge Nutraceuticals

Emerge Nutraceuticals is a nutraceutical manufacturer selling proprietary soft gels, powders, and liquid formulations for vitamins, proteins and the body-building industry. The company has their own branded products in addition to wholesale and white label manufacturing.

About Cholesterade

Cholesterade® was created by the late Dr. Robert Cade, the creator of Gatorade®. Cholesterade provides a natural, delicious and economical solution to help meet NIH requirements for therapeutic lifestyles changes using non-drug intervention to lower cholesterol prior to consideration of statin intervention.

Forward-Looking Statements Disclosure:

This press release may contain "forward-looking statements" within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company's expected future business and financial performance, and often contain words such as "anticipates," "beliefs," "estimates," "expects," "intends," " plans," "seeks," "will," and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Contact:

Keith Thomas, CEO
Metwood Inc
IR@emergenutra.com

James Price
Chairman/CEOat Go Epic Health Inc
P: (858) 525-5695
E: JamesPrice@LeoneAsset.com

SOURCE: Metwood, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708908/Emerge-Nutraceuticals-a-Wholly-Owned-Subsidiary-of-Metwood-Inc-Signs-MOU-to-Acquire-Cholesterade

© 2022 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.